Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey


Creative Commons License

Ozmen V., Atasoy A., GÖKMEN E., Ozdogan M., Guler N., URAS C., ...Daha Fazla

CUREUS, cilt.8, sa.3, 2016 (Hakemli Dergi) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 8 Sayı: 3
  • Basım Tarihi: 2016
  • Doi Numarası: 10.7759/cureus.522
  • Dergi Adı: CUREUS
  • Anahtar Kelimeler: breast cancer, adjuvant treatment, oncotype dx, decision impact, genomic testing, INTERNATIONAL EXPERT CONSENSUS, BREAST-CANCER, PRIMARY THERAPY, RECOMMENDATIONS, CHEMOTHERAPY, WOMEN, ASSAY, MANAGEMENT, EXPRESSION, PATTERNS
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Introduction: Breast cancer is the most common malignancy among Turkish women and the rate of early stage disease is increasing. The Oncotype DX (R) 21-gene assay is predictive of distant recurrence in ER-positive, HER2-negative early breast cancer. We aimed to evaluate the impact of the Recurrence Score (R) (RS) on treatment decisions and physician perceptions in Turkey. We also studied correlations between RS and routine risk factors.